Sprint Bioscience AB (OSTO:SPRINT) EBIT: kr90.0 Mil (TTM As of Mar. 2026)


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr4.06
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB EBIT?

Sprint Bioscience AB OSTO:SPRINT -4.92% 32 EBIT is kr90.0 Mil as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sprint Bioscience AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-12.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr90.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sprint Bioscience AB's annualized ROC % for the quarter that ended in Mar. 2026 was -373.14%. Sprint Bioscience AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,423.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sprint Bioscience AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.12%.


Sprint Bioscience AB  (OSTO:SPRINT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sprint Bioscience AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-57.236 * ( 1 - 0% )/( (16.874 + 13.804)/ 2 )
=-57.236/15.339
=-373.14 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sprint Bioscience AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-51.288/( ( (3.737 + max(-15.594, 0)) + (3.467 + max(-12.686, 0)) )/ 2 )
=-51.288/( ( 3.737 + 3.467 )/ 2 )
=-51.288/3.602
=-1,423.88 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.003 + 0 + 1.887) - (4.402 + 0 + 13.082)
=-15.594

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.4210854715202E-14) - (2.404 + 0 + 10.282)
=-12.686

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sprint Bioscience AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=90.007/320.064
=28.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB EBIT Related Terms


Sprint Bioscience AB EBIT Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB EBIT Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.81 0.00 -2.53 -18.24 92.16

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.87 -6.69 -8.33 117.85 -12.82

OSTO:SPRINT vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's EV-to-EBIT falls into.


OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr90.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr90.0 Mil mean?
Sprint Bioscience AB (OSTO:SPRINT) has a EBIT of kr90.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sprint Bioscience AB.
Is Sprint Bioscience AB's EBIT too high?
Sprint Bioscience AB's current EBIT is kr90.0 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's EBIT compare to VRTX and REGN?
Sprint Bioscience AB's EBIT of kr90.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sprint Bioscience AB. Sprint Bioscience AB's current EBIT is kr90.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current EBIT is kr90.0 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current EBIT is kr90.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • EBIT: kr90.0 Mil
  • GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.06
Price
kr2.18
GF Value